Palo Alto, Calif. (March 15, 2017) – Syapse, a market leader in precision oncology solutions, announced today that Ken Tarkoff is joining the company as its new Chief Executive Officer (CEO). Ken, a health technology industry veteran who has held leadership roles at several cutting-edge companies, brings deep experience in facilitating physician, health system, and health plan relationships. Previously, Ken served as Chief Operating Officer (COO) for RelayHealth and Senior Vice President and General Manager at RelayHealth after it was acquired by McKesson.
Ken joins Syapse during a period of rapid growth for the company, in offerings, customers, and capabilities. Leading health systems, including Intermountain Healthcare, Providence St. Joseph Health, Stanford Cancer Institute, Catholic Health Initiatives, Dignity Health, Henry Ford Health System, and Cancer Treatment Centers of America, have adopted Syapse to manage nearly one million active cancer cases throughout 285 hospitals across 25 states. The company is backed by some of the top health care investors including Ascension Ventures, Safeguard Scientifics (NYSE:SFE), Social Capital, GE Ventures, and Intermountain Healthcare Innovation Fund I, LP.
“Precision medicine has the power to transform health care, delivering better treatments and better outcomes. I’m excited to join Syapse, a company uniquely positioned to drive this transformation,” said Ken Tarkoff, Syapse’s new CEO. “With its innovative model and unmatched network, Syapse can help more physicians offer effective and cost-efficient treatments so that patients get better, faster.”
With the adoption of precision medicine, physicians are now able to deliver personalized care that matches patients with targeted, cutting-edge therapies based on their individual genomic makeup. This change results in better care and outcomes that are ultimately more cost-effective for both patients and providers. Currently, the challenge for providers is making sense of the fragmented clinical, molecular, and outcomes data needed to deliver these treatments at scale. Syapse offers a robust platform that brings together all of this data for delivery within a physician's workflow. The Syapse network provides physicians access to the largest, real-world precision oncology data sharing consortium in the world.
“We are thrilled to have Ken on board as CEO of Syapse,” said Syapse Chairman Gary Kurtzman. “Effectively treating cancer is one of the greatest – and costliest – challenges in health care. Precision medicine can change that, and scores of health systems and providers are rushing to integrate it into their care. With Ken’s leadership, Syapse will help make precision medicine the reality for more health systems, providers, and most importantly, more patients.”
As CEO, Ken will help Syapse transform health care by making precision medicine available to more patients nationwide through new and expanded partnerships with health systems and other health care stakeholders. At RelayHealth, Ken launched many new innovations and scaled technology solutions in the clinical and financial decision support spaces, including co-founding and being a service provider for the CommonWell Health Alliance and leading the worldwide deployment of the Patient Centered Medical Home initiative for the U.S. Department of Defense. Previously, Ken was the Director of Supplier Services at Xign Corporation, Vice President of Product Management for Questium, and Vice President of Regional Operations at Vivra Specialty Partners.
Syapse is a market leader in precision oncology solutions that helps health systems and providers deliver cutting-edge treatments, resulting in better health outcomes and lower costs. Syapse offers a robust software platform that brings together previously fragmented clinical, molecular, and outcomes data for delivery within a physician's workflow. In addition, Syapse customers have access to the Syapse network, the largest precision oncology data-sharing consortium in the world. Leading health systems, including Intermountain Healthcare, Providence St. Joseph Health, and Stanford Cancer Institute, have adopted Syapse to manage nearly one million active cancer cases across 25 States and in nearly 300 hospitals. The company was founded by Stanford-trained scientists and is backed by Ascension Ventures, Safeguard Scientifics (NYSE:SFE), Social Capital, GE Ventures, Intermountain Healthcare Innovation Fund I, LP. For more information, visit https://syapse.com/ or follow us on Twitter, LinkedIn, or Facebook.